InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Foley Mark J, Director. Director active across 2 companies, notably GLAUKOS Corp. In total, 12 reports have been published. Total volume traded: €914k. The latest transaction was disclosed on 2 June 2022 — Attribution. Regulator: SEC (Form 4). All data is free.
Declarations12 total
04,364 shares0
Common Stock
SEC:0001104659-22-068667:0·
€47,6743,304 shares@ €14.42911.8% of flow
Common Stock
SEC:0001209191-22-019723:0·
02,486 shares0
Common Stock
SEC:0001104659-22-001661·
02,486 shares0
Common Stock
SEC:0001104659-22-001661:0·
€456,84640,000 shares@ €11.421134.8% of flow
Common Stock
SEC:0001479290-21-000169·
Ideal exit: 26 Aug 2022 (T+270)
€456,84640,000 shares@ €11.421117.1% of flow
Common Stock
SEC:0001479290-21-000169:0·
Ideal exit: 26 Aug 2022 (T+270)
€837,59542,096 shares@ €19.897363.8% of flow
Common Stock
SEC:0001479290-21-000158·
€837,59542,096 shares@ €19.897331.3% of flow
Common Stock
SEC:0001479290-21-000158:0·
€17,919882 shares@ €20.31671.4% of flow
Common Stock
SEC:0001479290-21-000130·
€17,919882 shares@ €20.31670.7% of flow
Common Stock
SEC:0001479290-21-000130:0·
02,382 shares0
Common Stock
SEC:0001104659-21-077837·
02,382 shares0
Common Stock
SEC:0001104659-21-077837:0·
12 of 12 declarations
About Foley Mark J
Mark J. Foley is a Board Member and President & CEO at GLAUKOS Corp and Revance Therapeutics, Inc. He oversees the operations and strategy of these companies. Foley is recognized for his expertise in health and biotechnology.
